Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
Previously approved prior authorizations and member status in step therapy will not change
This DPP-4 inhibitor is contraindicated in this patient group on the basis of the respective cardiovascular safety study that has shown a significant increase of hospitalization for heart failure as secondary endpoint in the saxagliptin arm (63, 66)
The pattern makes biological sense
The CagriSema combination (cagrilintide plus semaglutide) has been studied in clinical trials, and some providers extend this logic to tirzepatide
-1775582746855.png&w=3840&q=75)
US$ 24.98
US$ 22.91
US$ 27.30
US$ 20.75
US$ 20.22
